They pointed out that the identification of SERT/serotonin pathway defects could also guide new therapeutic strategies targeting their functions in infants with pulmonary hypertension and its lethal form—alveolar capillary dysplasia with pulmonary vein malposition. This evidence concerns the gene SLC6A4 and pulmonary hypertension.